Press coverage about Aduro BioTech (NASDAQ:ADRO) has been trending somewhat positive on Sunday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aduro BioTech earned a news impact score of 0.19 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.9581763335947 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
A number of equities research analysts have weighed in on ADRO shares. HC Wainwright set a $10.00 price objective on shares of Aduro BioTech and gave the stock a “buy” rating in a report on Tuesday, January 16th. Oppenheimer set a $15.00 price objective on shares of Aduro BioTech and gave the stock a “buy” rating in a report on Monday, December 11th. Canaccord Genuity set a $30.00 price objective on shares of Aduro BioTech and gave the stock a “buy” rating in a report on Thursday, December 14th. Cantor Fitzgerald restated a “buy” rating and issued a $15.00 price objective on shares of Aduro BioTech in a report on Monday, March 5th. Finally, Zacks Investment Research upgraded shares of Aduro BioTech from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a report on Tuesday, March 6th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $14.50.
Shares of Aduro BioTech (NASDAQ:ADRO) opened at $9.20 on Friday. Aduro BioTech has a fifty-two week low of $5.82 and a fifty-two week high of $14.05. The company has a market cap of $745.26, a P/E ratio of -7.30 and a beta of 2.75.
In other news, insider Stephen T. Isaacs sold 7,949 shares of the stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $7.95, for a total transaction of $63,194.55. Following the sale, the insider now owns 213,695 shares in the company, valued at $1,698,875.25. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Stephen T. Isaacs sold 72,051 shares of the stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $8.48, for a total transaction of $610,992.48. Following the sale, the insider now owns 231,380 shares in the company, valued at approximately $1,962,102.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 109,758 shares of company stock worth $894,724. Corporate insiders own 6.60% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/03/18/aduro-biotech-adro-earns-news-impact-rating-of-0-19.html.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.